Campbell & Co Investment Adviser’s Sage Therapeutics SAGE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-141,795	Closed	-$1.13M	–	1426
2025 Q1	$1.13M	Buy	+141,795	New	+$1.04M	0.09%	380
2024 Q2	–	Sell	-49,274	Closed	-$923K	–	1310
2024 Q1	$923K	Buy	+49,274	New	+$1.14M	0.08%	433
2021 Q1	–	Sell	-3,448	Closed	-$298K	–	588
2020 Q4	$298K	Buy	+3,448	New	+$254K	0.18%	235

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Campbell & Co Investment Adviser's SAGE Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 141,795 shares — an estimated $1.13M sold.

Campbell & Co Investment Adviser first reported a position in SAGE in Q4 2020 and held it in 3 quarters. The position peaked at $1.13M in Q1 2025. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Campbell & Co Investment Adviser reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 141,795 Sage Therapeutics shares in Q2 2025, an estimated $1.13M.
Campbell & Co Investment Adviser first reported a position in Sage Therapeutics in Q4 2020 and held it in 3 quarters.
Campbell & Co Investment Adviser's Sage Therapeutics position peaked at $1.13M in Q1 2025.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.